1 day Ago By Defense World Staff
Clene ( NASDAQ:CLNN – Get Free Report ) ‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $31.00 price target on the stock.
HC Wainwright’s price target points to a potential upside of 486.01% from the stock’s current price. A number of other analysts have also recently issued reports on CLNN.
Benchmark reissued a “buy” rating and set a $100.00 price objective on shares of Clene in a research report on Thursday, May 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $94.
00 price target on shares of Clene in a research note on Tuesday, August 6th. Finally, EF Hutton Acquisition Co. I upgraded Clene to a “strong-buy” rating in a report on Tuesday, September 10th.
Get Our Latest Stock Analysis on Clene Clene Stock Down 5.4 % Clene ( NASDAQ:CLNN – Get Free Report ) last released its earnings results on Wednesday, August 7th. The company reported ($1.
06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.54.
The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.10 million.
Clene had a negative return on equity of 315.97% and a negative net margin of 6,890.50%.
As a group, research analysts expect that Clene will post -5.26 earnings per share for the current year. Hedge Funds Weigh In On Clene An institutional investor recently raised its position in Clene stock.
Csenge Advisory Group increased its stake in Clene Inc. ( NASDAQ:CLNN – Free Report ) by 131.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 269,600 shares of the company’s stock after purchasing an additional 153,000 shares during the period. Csenge Advisory Group owned 0.21% of Clene worth $96,000 as of its most recent SEC filing.
23.28% of the stock is currently owned by institutional investors. About Clene ( Get Free Report ) Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. See Also Five stocks we like better than Clene 3 Natural Gas Stocks That Offer Great Dividend Yields Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? 3 Best Fintech Stocks for a Portfolio Boost Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What is Insider Trading? What You Can Learn from Insider Trading Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter .
.
